Designed to simplify for EIT Health Partners to access and establish collaborations, to leverage the innovation potential of these goldmines of information.
Prostate cancer test developed in record time thanks to biobank access
Stockholm3 is a new blood-based test to predict the risk for aggressive prostate cancer. The Stockholm3 test reduces the number of unnecessary biopsies by 50%, and can also find aggressive cancer in men with low PSA values. It would have been impossible to develop the Stockholm3 test without access to large patient registers and biobanks.
Are you an Innovator? Why use biobanks and registers?
Are you a start-up, innovator or researcher? Via health data registers and biobanks you can shorten time-to-market through product validation, cost-benefit analysis, impact prediction and access to expertise.
As a biobank or register owner, you will get increased exposure, knowledge of industry needs, increased use of samples and data, and possible sources of revenue.
Cost-benefit analysis: how biobanks and health data add value
Biobanks and health data registers provided an unmatched resource when performing a cost-benefit analysis for new healthcare treatments or protocols. Find out more about using these goldmines of information.
